Nifty
Sensex
:
:
18534.40
62622.24
-99.45 (-0.53%)
-346.89 (-0.55%)

Pharmaceuticals & Drugs - Global

Rating :
29/99

BSE: 530549 | NSE: SHILPAMED

238.80
31-May-2023
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  • 239.70
  • 241.35
  • 238.00
  • 239.45
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  130332
  •  312.00
  •  457.00
  •  222.60

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 2,077.60
  • N/A
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 2,725.40
  • 0.46%
  • 1.17

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 50.01%
  • 7.91%
  • 24.05%
  • FII
  • DII
  • Others
  • 10.25%
  • 3.48%
  • 4.30%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.92
  • 7.75
  • 8.06

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.96
  • 5.45
  • -1.67

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 2.51
  • -11.61
  • -27.09

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 37.27
  • 27.51
  • 57.06

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 3.63
  • 2.37
  • 2.32

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 22.28
  • 19.32
  • 21.21

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 23
Mar 22
Var%
Dec 22
Dec 21
Var%
Sep 22
Sep 21
Var%
Jun 22
Jun 21
Var%
Net Sales
263.56
340.59
-22.62%
262.50
272.30
-3.60%
262.91
295.27
-10.96%
261.16
237.36
10.03%
Expenses
225.34
266.87
-15.56%
231.21
227.21
1.76%
250.71
242.11
3.55%
240.59
205.48
17.09%
EBITDA
38.23
73.73
-48.15%
31.29
45.09
-30.61%
12.20
53.16
-77.05%
20.57
31.88
-35.48%
EBIDTM
14.50%
21.65%
11.92%
16.56%
4.64%
18.00%
7.88%
13.43%
Other Income
2.17
5.49
-60.47%
2.74
5.48
-50.00%
4.39
1.28
242.97%
8.10
1.99
307.04%
Interest
17.74
9.35
89.73%
17.86
9.92
80.04%
13.47
11.58
16.32%
9.59
10.32
-7.07%
Depreciation
25.69
22.34
15.00%
24.08
20.65
16.61%
23.31
19.18
21.53%
22.42
17.63
27.17%
PBT
-3.03
47.41
-
-7.91
20.00
-
-20.20
32.59
-
-3.34
5.92
-
Tax
3.82
16.86
-77.34%
-0.96
9.71
-
-3.81
11.56
-
-6.41
3.56
-
PAT
-6.85
30.55
-
-6.95
10.29
-
-16.38
21.03
-
3.08
2.36
30.51%
PATM
-2.60%
8.97%
-2.65%
3.78%
-6.23%
7.12%
1.18%
1.00%
EPS
-0.93
3.40
-
-0.76
1.10
-
-2.15
2.45
-
0.10
0.19
-47.37%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Net Sales
1,050.13
1,145.52
901.13
907.91
733.39
788.83
779.16
716.43
613.80
571.38
371.32
Net Sales Growth
-8.33%
27.12%
-0.75%
23.80%
-7.03%
1.24%
8.76%
16.72%
7.42%
53.88%
 
Cost Of Goods Sold
415.41
383.22
270.73
277.73
257.03
355.87
371.81
366.19
323.16
313.26
213.95
Gross Profit
634.72
762.30
630.40
630.18
476.36
432.95
407.36
350.25
290.63
258.12
157.38
GP Margin
60.44%
66.55%
69.96%
69.41%
64.95%
54.89%
52.28%
48.89%
47.35%
45.17%
42.38%
Total Expenditure
947.85
948.32
729.43
693.39
579.39
637.60
617.55
556.44
487.38
455.40
301.63
Power & Fuel Cost
-
52.43
40.25
38.76
33.57
28.86
26.30
21.90
19.29
17.37
10.67
% Of Sales
-
4.58%
4.47%
4.27%
4.58%
3.66%
3.38%
3.06%
3.14%
3.04%
2.87%
Employee Cost
-
264.49
235.31
196.59
176.40
149.35
127.87
90.09
82.30
67.83
42.56
% Of Sales
-
23.09%
26.11%
21.65%
24.05%
18.93%
16.41%
12.57%
13.41%
11.87%
11.46%
Manufacturing Exp.
-
124.11
91.29
79.19
61.23
59.96
52.55
45.35
36.55
27.44
16.92
% Of Sales
-
10.83%
10.13%
8.72%
8.35%
7.60%
6.74%
6.33%
5.95%
4.80%
4.56%
General & Admin Exp.
-
71.58
47.71
70.26
27.20
22.50
16.95
14.11
10.64
9.53
9.51
% Of Sales
-
6.25%
5.29%
7.74%
3.71%
2.85%
2.18%
1.97%
1.73%
1.67%
2.56%
Selling & Distn. Exp.
-
25.29
18.63
10.40
6.72
6.37
4.75
7.27
5.99
7.29
4.43
% Of Sales
-
2.21%
2.07%
1.15%
0.92%
0.81%
0.61%
1.01%
0.98%
1.28%
1.19%
Miscellaneous Exp.
-
27.22
25.51
20.47
17.23
14.68
17.32
11.54
9.45
12.68
4.43
% Of Sales
-
2.38%
2.83%
2.25%
2.35%
1.86%
2.22%
1.61%
1.54%
2.22%
0.97%
EBITDA
102.29
197.20
171.70
214.52
154.00
151.23
161.61
159.99
126.42
115.98
69.69
EBITDA Margin
9.74%
17.21%
19.05%
23.63%
21.00%
19.17%
20.74%
22.33%
20.60%
20.30%
18.77%
Other Income
17.40
20.90
40.09
22.22
15.56
32.62
29.34
11.36
6.93
9.12
5.01
Interest
58.66
41.17
21.87
4.56
3.68
2.66
3.13
3.93
4.05
3.52
2.27
Depreciation
95.50
79.80
53.98
43.78
42.06
37.22
30.64
23.14
21.41
23.22
15.34
PBT
-34.48
97.13
135.95
188.40
123.82
143.96
157.17
144.28
107.89
98.35
57.10
Tax
-7.36
41.68
48.85
33.49
26.18
33.91
42.04
35.62
35.22
20.30
9.53
Tax Rate
21.35%
39.35%
24.82%
17.78%
18.22%
23.56%
27.54%
25.11%
32.66%
21.27%
16.72%
PAT
-27.10
60.66
147.78
156.50
120.28
112.43
113.71
109.84
73.69
75.67
47.35
PAT before Minority Interest
-28.66
60.58
146.20
154.91
117.52
110.05
110.59
106.24
72.62
75.15
47.47
Minority Interest
-1.56
0.08
1.58
1.59
2.76
2.38
3.12
3.60
1.07
0.52
-0.12
PAT Margin
-2.58%
5.30%
16.40%
17.24%
16.40%
14.25%
14.59%
15.33%
12.01%
13.24%
12.75%
PAT Growth
-142.19%
-58.95%
-5.57%
30.11%
6.98%
-1.13%
3.52%
49.06%
-2.62%
59.81%
 
EPS
-3.12
6.99
17.03
18.03
13.86
12.95
13.10
12.65
8.49
8.72
5.46

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Shareholder's Funds
1,822.19
1,478.67
1,329.36
1,197.58
1,085.03
986.90
639.26
546.94
396.45
320.42
Share Capital
8.68
8.15
8.15
8.15
8.15
8.01
7.71
7.71
7.36
4.90
Total Reserves
1,813.51
1,470.51
1,321.21
1,189.43
1,076.88
978.88
631.55
539.23
389.09
315.52
Non-Current Liabilities
452.82
561.37
256.94
166.62
153.48
251.26
67.23
154.15
104.53
98.51
Secured Loans
353.49
473.87
164.48
80.39
67.09
141.20
0.03
71.03
37.43
70.47
Unsecured Loans
0.11
0.35
0.53
0.70
1.03
1.30
0.00
31.30
30.05
0.00
Long Term Provisions
19.08
15.48
26.17
21.77
20.32
16.89
13.96
11.75
9.93
6.92
Current Liabilities
611.54
543.29
410.82
253.44
265.84
236.90
222.07
189.06
166.84
123.77
Trade Payables
146.04
67.25
92.55
80.72
103.74
111.86
106.48
75.50
92.98
51.26
Other Current Liabilities
240.13
219.33
142.10
81.62
59.59
28.03
36.49
49.32
38.23
23.38
Short Term Borrowings
202.90
243.40
165.27
86.58
98.12
92.41
74.10
58.47
30.27
45.07
Short Term Provisions
22.46
13.31
10.89
4.52
4.39
4.60
5.00
5.77
5.37
4.06
Total Liabilities
2,875.50
2,572.16
1,989.21
1,610.02
1,499.13
1,472.22
930.89
904.54
677.83
551.42
Net Block
1,341.84
1,110.53
650.44
558.01
534.20
491.93
393.41
316.06
294.42
180.67
Gross Block
1,725.77
1,421.10
986.42
853.16
793.24
704.89
582.20
476.34
448.38
300.89
Accumulated Depreciation
383.93
310.57
335.98
295.15
259.04
212.96
188.79
160.28
153.96
120.22
Non Current Assets
1,988.30
1,729.60
1,365.35
1,064.96
827.16
742.33
576.68
576.77
443.89
339.18
Capital Work in Progress
506.18
541.29
666.25
429.12
209.85
140.51
91.90
221.62
111.03
129.15
Non Current Investment
34.23
21.22
10.45
2.25
20.79
27.99
34.15
0.19
0.21
0.14
Long Term Loans & Adv.
93.90
43.10
32.42
48.75
37.47
77.09
51.86
38.74
38.18
28.82
Other Non Current Assets
12.15
13.46
5.78
26.84
24.86
4.80
5.36
0.16
0.06
0.40
Current Assets
887.19
818.99
623.85
545.06
671.97
729.88
354.21
327.61
233.74
211.99
Current Investments
0.00
0.00
0.00
0.00
119.54
224.62
59.63
65.35
10.14
50.28
Inventories
355.24
316.84
226.43
187.67
188.71
190.00
134.23
130.78
123.25
74.33
Sundry Debtors
386.33
217.50
246.79
203.73
220.27
170.93
125.43
81.37
67.96
41.79
Cash & Bank
34.11
123.11
44.56
94.54
73.83
100.39
11.03
18.42
9.19
16.87
Other Current Assets
111.52
98.73
76.81
45.04
69.62
43.95
23.90
31.69
23.20
28.72
Short Term Loans & Adv.
102.16
62.81
29.25
14.08
43.54
21.95
8.90
4.91
3.23
2.86
Net Current Assets
275.66
275.69
213.04
291.62
406.13
492.98
132.14
138.55
66.90
88.22
Total Assets
2,875.49
2,548.59
1,989.20
1,610.02
1,499.13
1,472.21
930.89
904.54
677.83
551.42

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Cash From Operating Activity
105.13
46.93
124.38
146.78
44.92
37.48
128.70
68.81
70.04
43.64
PBT
102.26
196.79
188.40
143.70
136.77
146.49
140.36
107.84
95.45
57.00
Adjustment
109.34
4.03
41.32
20.44
18.83
17.19
20.61
26.46
19.62
11.52
Changes in Working Capital
-71.99
-106.29
-63.15
18.71
-69.66
-92.61
-2.70
-40.11
-23.44
-13.90
Cash after chg. in Working capital
139.62
94.53
166.57
182.85
85.94
71.08
158.27
94.19
91.62
54.62
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-34.48
-47.60
-42.20
-36.07
-41.02
-33.60
-29.56
-25.38
-21.58
-10.98
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-285.50
-404.28
-289.52
-196.16
-8.76
-262.23
-109.20
-195.18
-48.93
-95.21
Net Fixed Assets
385.38
-272.02
-4.28
-256.96
-136.75
-172.23
-92.14
-78.46
-61.02
-83.52
Net Investments
-18.18
-125.84
-4.44
141.85
95.51
-172.72
-14.09
-64.38
12.08
13.84
Others
-652.70
-6.42
-280.80
-81.05
32.48
82.72
-2.97
-52.34
0.01
-25.53
Cash from Financing Activity
82.86
436.37
175.50
10.06
-60.91
312.70
-19.65
135.05
-28.34
66.31
Net Cash Inflow / Outflow
-97.51
79.03
10.36
-39.32
-24.75
87.95
-0.15
8.68
-7.23
14.74
Opening Cash & Equivalents
122.85
44.31
34.13
73.83
99.97
7.05
3.61
9.19
16.87
2.27
Closing Cash & Equivalent
25.34
123.34
44.31
34.36
73.83
99.97
6.43
18.42
9.19
16.87

Financial Ratios

Consolidated /

Standalone
Description
Mar 22
Mar 21
Mar 20
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Book Value (Rs.)
209.93
181.37
163.06
146.89
133.09
123.17
82.91
70.92
107.72
43.52
ROA
2.20%
6.33%
8.61%
7.56%
7.41%
9.20%
11.58%
9.18%
12.23%
9.64%
ROE
3.67%
10.41%
12.26%
10.30%
10.62%
13.60%
17.92%
15.40%
20.98%
15.93%
ROCE
5.94%
10.73%
12.41%
11.05%
11.71%
15.91%
19.90%
17.90%
20.48%
15.04%
Fixed Asset Turnover
0.73
0.75
0.99
0.89
1.06
1.22
1.36
1.34
1.54
1.32
Receivable days
98.75
94.03
90.56
105.51
90.20
69.00
52.26
43.99
34.62
39.70
Inventory Days
109.68
110.03
83.24
93.66
87.32
75.49
66.97
74.84
62.33
68.31
Payable days
106.00
107.72
47.69
58.00
61.51
60.89
60.10
62.86
57.06
63.94
Cash Conversion Cycle
102.43
96.33
126.11
141.17
116.00
83.61
59.13
55.97
39.90
44.07
Total Debt/Equity
0.37
0.57
0.29
0.16
0.18
0.24
0.14
0.34
0.30
0.41
Interest Cover
3.48
9.92
42.34
40.09
55.10
49.69
37.07
27.63
28.09
26.13

News Update:


  • Shilpa Medicare gets USFDA’s approval for New Drug Application for Pemetrexed Injection
    23rd May 2023, 15:39 PM

    This product is required to be administered intravenously without any further dilution

    Read More
  • Shilpa Medicare gets USFDA’s final nod for Apremilast Tablets
    11th Apr 2023, 09:24 AM

    The US market for Apremilast Tablets, 10 mg, 20 mg, and 30 mg is around $3.55 billion

    Read More
  • USFDA inspects Shilpa Medicare’s Analytical Services Division in Hyderabad
    11th Mar 2023, 16:52 PM

    The inspection is closed with 2 minor observations

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.